Sanome is developing novel AI technology to combine biomarkers into diagnostics, to detect early health changes. This early warning system solution is deployable across all settings, changing healthcare for good. Specifically, these detections will reduce hospitalisations;support effective rehabilitation;enable efficient and cost-reducing triaging; whilst enabling early interventions and ensuring preventable deaths remain prevented – the power of Sanome’s technology and the possibility for it to underpin and support all aspects of the healthcare system continues to push the boundaries of what has been achieved before. Sanome has successfully launched clinical trials in the UK and internationally this quarter.